Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

19 Jul 2023

Abstract excerpt

Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season. In this pre-specified analysis, isolates from RSV infections were subtyped, sequenced and analyzed for nirsevimab binding site substitutions;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37468530
DOI: 10.1038/s41467-023-40057-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsPMID 37468530Read ↗

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.Semantic proximity Read ↗

Respiratory Syncytial virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisSemantic proximity Read ↗

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.Semantic proximity Read ↗

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.Semantic proximity Read ↗

Complete definition of how antibodies used to prevent RSV are affected by F mutationsSemantic proximity Read ↗

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world studySemantic proximity Read ↗

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance ProfilesSemantic proximity Read ↗

A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S.Semantic proximity Read ↗

Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolatesSemantic proximity Read ↗

Functional Characterization of RSV Clades Associated with Prophylactic Breakthrough Infections in Pediatric Transmission ClustersSemantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.